EMBC
Unloved QualityAI neutralEmbecta Corp. · Healthcare · United States · $380M cap · $5.7M/day traded
$6.43 +0.3% · close 10 Nov · scored 11 Nov
Unloved Quality: Strong and cheap, but the market has not warmed to it.
As of 11 Nov 2026, the MoatMap Score for Embecta Corp. (EMBC) is 97/100, ranked against 25,000+ stocks in 38 markets (Quality 78, Value 84, Momentum 48, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
Embecta is the former BD diabetes care unit that sells insulin pen needles and syringes worldwide. It generates meaningful cash, bought back about 4.8% of shares in the last 90 days, and insiders have been buying. The share price fell about 57% after insulin pen problems and is now the subject of securities lawsuits. The core product faces long-term pressure from insulin pumps and GLP-1 drugs, and the company carries heavy debt.
ABOUT EMBECTA CORP.
Read
Embecta Corp. is a pure-play global medical device company dedicated exclusively to diabetes care, offering a comprehensive portfolio of insulin delivery solutions including pen needles and syringes. Spun off from Becton Dickinson, the company holds a leading market position globally, leveraging extensive distribution networks and established brand trust among patients and healthcare providers. This specialized focus ensures deep expertise and market penetration in a critical healthcare segment.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.1B | 1.1B | 1.1B | 1.1B | -1.5% | 1.0B | 1.0B | 1.1B | 0.1% |
| EPS | 3.92 | 1.23 | 1.36 | 1.64 | -25.2% | 1.47 | 1.02 | 0.98 | -22.7% |
| Shares | 57.1M | 57.3M | 57.7M | 58.5M | +2.5% | 56.7M | — | — | — |
| Debt | 1.6B | 1.6B | 1.6B | 1.4B | -4.5% | 1.5B | — | — | — |
| Equity | -891.4M | -821.7M | -738.9M | -651.2M | — | — | — | — | — |
| Op CF | 412.2M | 67.7M | 35.7M | 191.7M | -22.5% | 174.1M | — | — | — |
| Inv CF | -24.0M | -26.5M | -15.8M | -9.3M | — | — | — | — | — |
| Fin CF | -48.0M | -48.7M | -73.4M | -226.7M | — | — | — | — | — |
133% above its 52-week low and back above a rising 50-day average.
The Momentum score still reads 48: it weighs six months of price and earnings revisions, so it trails a turn like this.
Swung more than 89% of stocks we rank over the past year (volatility 82% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EMBC are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| EMBC | Embecta Corp.(you) | $380M | 97 |
| UTMD | Utah Medical Products, Inc. | $236M | 95 |
| PDEX | Pro-Dex, Inc. | $201M | 89 |
| SMTI | Sanara MedTech Inc. | $301M | 61 |
| NVST | Envista Holdings Corporation | $3.8B | 89 |
| OSUR | OraSure Technologies, Inc. | $285M | 40 |
| MMSI | Merit Medical Systems, Inc. | $5.6B | 88 |
| ANGO | AngioDynamics, Inc. | $520M | 34 |
| ICUI | ICU Medical, Inc. | $4.2B | 72 |
| ALGN | Align Technology, Inc. | $11.0B | 88 |
Peer medians: ROE -30.5% · P/E 26.3x · Gross margin 63.3%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.